Perspectives on the Impact of Inflammation in OA

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Introduction

Pathologic Changes in OA Joints

Role of Proinflammatory Cytokines in the Pathophysiology of OA

Patient Case Presentation

Further Assessment and Conservative Therapy

Patient Case (cont)

Important Considerations for Oral NSAID Use and Selection

Place of Opioids in Knee OA

Patient Case, 2 Years Later

IA-CS Injections for Knee OA

Efficacy of IA-CS Injections in Knee OA

Effects of IA Injection of TA on Knee Pain and Knee Cartilage Volume

Concerns and Contraindications With IA-CS Use

IA Extended-Release Formulation of TA for Knee OA

Phase 3 Study on Extended-Release TA for Knee OA Pain

Use of Extended-Release TA in Practice

Overview of Other Injectable Therapies Orthobiologics

Patient Case (cont) When Is Knee Replacement Appropriate?

IA Injections in Practice

Investigational Therapies for OA

Concluding Remarks

Abbreviations

Abbreviations (cont)